Abstract

BackgroundThe Gaussia princeps luciferase is used as a stand-alone reporter of transgene expression for in vitro and in vivo expression systems due to the rapid and easy monitoring of luciferase activity. We sought to simultaneously quantitate production of other recombinant proteins by transcriptionally linking the Gaussia princeps luciferase gene to other genes of interest through the foot-and-mouth disease virus 2A translational interrupter sequence.ResultsWe produced six plasmids, each encoding a single open reading frame, with the foot-and-mouth disease virus 2A sequence placed either N-terminal or C-terminal to the Gaussia princeps luciferase gene. Two plasmids included novel Gaussia princeps luciferase variants with the position 1 methionine deleted. Placing a foot-and-mouth disease virus 2A translational interrupter sequence on either the N- or C-terminus of the Gaussia princeps luciferase gene did not prevent the secretion or luminescence of resulting chimeric luciferase proteins. We also measured the ability of another polycistronic plasmid vector with a 2A-luciferase sequence placed downstream of the foot-and-mouth disease virus P1 and 3C protease genes to produce of foot-and-mouth disease virus-like particles and luciferase activity from transfected cells. Incorporation of the 2A-luciferase sequence into a transgene encoding foot-and-mouth disease virus structural proteins retained luciferase activity and the ability to form virus-like particles.ConclusionsWe demonstrated a mechanism for the near real-time, sequential, non-destructive quantitative monitoring of transcriptionally-linked recombinant proteins and a valuable method for monitoring transgene expression in recombinant vaccine constructs.

Highlights

  • The Gaussia princeps luciferase is used as a stand-alone reporter of transgene expression for in vitro and in vivo expression systems due to the rapid and easy monitoring of luciferase activity

  • We evaluated the ability of one chimera to function as the 3′ terminus of a transgene encoding a Foot-andmouth disease virus (FMDV) P1-2A-3C cassette known to produce Virus-like particle (VLP)

  • Design of six bicistronic Gaussia princeps luciferase (GLuc)/super-luminescent GLuc variant (SGLuc) constructs A total of six bicistronic GLuc/SGLuc constructs were evaluated for retention of secretion and ability to luminesce (Fig. 1a)

Read more

Summary

Introduction

The Gaussia princeps luciferase is used as a stand-alone reporter of transgene expression for in vitro and in vivo expression systems due to the rapid and easy monitoring of luciferase activity. Real-time sequential monitoring of recombinant protein production is advantageous over single-event, terminal monitoring that requires destruction of expressing cells in vitro or the ex vivo analysis of clinical samples. Transfected cell cultures may require lysis for detection of recombinant proteins of interest through polyacrylamide gel electrophoresis, western blots, ELISA, indirect fluorescent antibody assay or other methods. These detection methods are time-consuming, costly and often require protein-specific antibody reagents. Monitoring in vivo expression of recombinant proteins is more problematic It requires invasive sampling at fewer time points, or terminal procedures, as well as protein-specific reagents. Using a secreted biomarker would be a useful tool for quantitating in vivo recombinant protein expression independent from host immune responses

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.